Navigation Links
Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
Date:9/30/2010

WALTHAM, Mass., Sept. 30 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) reported today that it has completed enrollment of patients in its Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.  This study is a double-blind, placebo-controlled trial designed to assess the efficacy of 8 weeks of treatment with RG2417 or a placebo on the symptoms of bipolar depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS).  The study enrolled 175 patients at 29 clinical sites within the United States, and we expect to report top-line results in the first quarter of 2011.

The primary objective of this study is to assess the safety and efficacy of RG2417 on the symptoms of bipolar depression by demonstrating a greater improvement in the MADRS score of the patients receiving RG2417 when compared to placebo over the 8-week treatment period.  Patients were initially screened for a score of bipolar depression symptoms of greater than 20 on the MADRS and subsequently confirmed to meet the criteria for bipolar depression using an alternate diagnostic tool to ensure that patients have the appropriate diagnosis for inclusion in the study.  Evaluations for symptoms of depression are conducted at baseline and then weekly using the MADRS, a standardized, rater-administered scale, which has been used for numerous drug trials in bipolar disorder.  In addition to the MADRS ratings, patients conduct a weekly self-assessment of their symptoms, which is used to cross check the fidelity of the MADRS raters.  Additional secondary and exploratory objectives include improvements in the Clinical Global Impression Scale, difference in the end of study MADRS scores, and a lack of increase in mania as measured by the Young's Mania Rating Scale.

The average baseline MADRS of the 175 patients
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
2. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
3. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
4. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
5. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
6. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
7. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
8. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
9. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
10. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
11. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... DSCM ), a leading online retailer of ... Tracy Wright, the Company,s chief finance officer will be ... community:Kaufman Bros. 13th Annual Investor ConferenceDate: Wednesday, September 15th, ... Hotel, 541 Lexington Avenue, New York City, NYThink Equity ...
... The U.S. Food and Drug Administration has approved ... a drug used to treat poisoning by organophosphate ... is approved to be administered either by intravenous ...   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo:   http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ...
Cached Medicine Technology:drugstore.com to Present at Upcoming Financial Conferences 2FDA Approves Pediatric Use of Chemical Poisoning Treatment 2
(Date:7/9/2014)... If you think winning is one of the key ... Winning along with other mental bonuses ranked near the bottom ... one of 11 big fun factors, according to a new ... when it comes to the "fun" factor, very little research ... into this elusive conceptuntil now. , The results of this ...
(Date:7/9/2014)... Medicine at the University of Pennsylvania in collaboration with ... million grant from the National Cancer Institute (NCI) to ... patients with malignant pleural mesothelioma, a rare, aggressive and ... lining of the lungs and is caused almost exclusively ... clinical trial and additional studies looking at the effects ...
(Date:7/9/2014)... stromal support cells and immune cells and the ... the development of diseases could open new therapeutic ... the conclusion of a review article by scientists from ... Nature . , Prof. Peter Carmeliet: "Consider the review ... cancer cells has been examined in minute detail for ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
(Date:7/9/2014)... than watching World Cup highlights, Brian Williams refreshing old ... unfortunate positions on railings. A University of Colorado Cancer ... shows that YouTube also allows researchers, journals, and ... topics of skin cancer and prevention. , "No matter ... of how we communicate around the world," says Chante ...
Breaking Medicine News(10 mins):Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2
... dressing well given by an emergency doctor. There is no need ... cold. A brisk walk and exposure to sunlight will do you ... you want to avoid the ill-effects of cold weather. Just putting ... the answer. ,Dr Goerge Danke, professor of emergency medicine ...
... According to new study, a protein in the eye has ... researchers say this could lead to promising treatments for other// ... ,Scientists from the Schepens Eye Research Institute in Boston ... a therapeutic drug. The drug can then prevent the onset ...
... that breathing oxygen may cause some harm to cells. The ... people //with severe lung or heart disease.Oxygen supports the organs ... the blood. But oxygen is often given inappropriately. Overall the ... life'. ,A study by researchers at New York Medical ...
... at University of Illinois at Chicago could possibly help ... Dean of the College of Nursing at UIC, //and ... which is using warm booties as a way to ... The idea, says Shaver, is that better sleep occurs ...
... loss followed by weight gain is only a health risk ... are now well established to many. But weight, once lost,// ... that fluctuating weight may, in itself, predispose to heart disease ... a group of 5,428 middle-aged British men during a 12 ...
... observed that yoga therapy can reduce risk factors and improve ... aid improve physical, psychological and spiritual //health - or so ... England, reviewed the best evidence they could find on the ... - out of 11 - trials that were good enough ...
Cached Medicine News:
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels....
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Liquichek Urine Chemistry Control is a liquid product ideal for monitoring urine chemistry testing procedures. It provides assayed values for urine tests commonly performed on chemistry analyzers and...
Medicine Products: